{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.9","upperLimit":"22.1","value":"13.8"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"14.6","value":"11.1"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"3.2","value":"1.9"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"2.0","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"163"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"description":"The time (in months) from the date of first dose of tazemetostat until the earliest date of disease progression or death from any cause. Per RECIST v1.0, CR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \\<10 mm in the short axis. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2"},{"description":"Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2"},{"description":"Patients with R/R DLBCL received 800 mg of tazemetostat monotherapy, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy"},{"description":"Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. In addition, these patients also received prednisolone 40 mg/m\\^2 on Days 1 to 5 and 15 to 19 from Cycle 1 to Cycle 4 post which tazemetostat monotherapy was continued.","id":"OG003","title":"Phase 2 Group 4: Tazemetostat + Prednisolone in R/R DLBCL Combination Therapy"}],"paramType":"MEDIAN","populationDescription":"Patients who had a response event per Independent Review Committee.","reportingStatus":"POSTED","timeFrame":"Radiologic tumor assessments performed at baseline (within 28 days before start of study treatment) and every 8 weeks during Cycles 2 to 6, and then every 12 weeks thereafter until confirmed PD/death, a maximum of approximately 82 months","title":"Progression Free Survival for Tazemetostat as a Single Agent or in Combination With Prednisolone (Phase 2 Only)","type":"SECONDARY","unitOfMeasure":"months"}